PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

Kang, Yoon‐Koo; Hwan Yook, Jeong; Park, Young-Kyu; Seok Lee, Jong; Kim, Young‐Woo; Young Kim, Jin; Ryu, Min‐Hee; Young Rha, Sun; Chung, Ik‐Joo; Kim, In‐Ho; Cheul Oh, Sang; Soo Park, Young; Son, Taeil; Ran Jung, Mi; Hwa Heo, Mi; Kyun Kim, Hark; Park, Cho‐Hyun; Hak Yoo, Chang; Choi, Jin‐Hyuk; Young Zang, Dae; Jin Jang, You; Young Sul, Ji; Gwang Kim, Jong; Su Kim, Beom; Beom, Seung‐Hoon; Cho, Sang‐Hee; Wan Ryu, Seung; Kook, Myeong‐Cherl; Ryoo, Baek‐Yeol; Ki Kim, Hyun; Yoo, Moon‐Won; Su Lee, Nam; Ho Lee, Sang; Kim, Gyunji; Lee, YeonJu; Hyun Lee, Jee; Hoon Noh, Sung

doi:10.1200/jco.20.02914

Public

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

Published in Journal of Clinical Oncology • Jun 16, 2021

Authors:

Yoon‐Koo Kang

Jeong Hwan Yook

Young-Kyu Park

Abstract

PURPOSE Adjuvant chemotherapy after D2 gastrectomy is standard for resectable locally advanced gastric cancer (LAGC) in Asia. Based on positive findings for perioperative chemotherapy in European phase III studies, the phase III PRODIGY study (ClinicalTrials.gov identifier: NCT01515748 ) investigate...

Subject

Medicine

Docetaxel

Oxaliplatin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!